Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)
Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...
Defiance Launches RKLX and HIMZ: 2X Leveraged ETFs for Rocket Lab and Hims & Hers
RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?